Short Interest in Prenetics Global Limited (NASDAQ:PRE) Increases By 46.2%

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 34,500 shares, an increase of 46.2% from the May 15th total of 23,600 shares. Based on an average trading volume of 21,200 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.4% of the shares of the stock are short sold.

Prenetics Global Price Performance

PRE remained flat at $7.01 during midday trading on Monday. 81,930 shares of the company’s stock traded hands, compared to its average volume of 19,125. Prenetics Global has a 52-week low of $3.09 and a 52-week high of $11.99. The company has a market capitalization of $85.56 million, a P/E ratio of -1.76 and a beta of 0.17. The firm has a fifty day moving average price of $6.32 and a 200-day moving average price of $5.53.

Prenetics Global (NASDAQ:PRE) last issued its earnings results on Thursday, June 12th. The company reported ($0.80) EPS for the quarter. The business had revenue of $17.31 million for the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. On average, research analysts anticipate that Prenetics Global will post -3.3 EPS for the current fiscal year.

Institutional Trading of Prenetics Global

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new stake in Prenetics Global Limited (NASDAQ:PRE) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global as of its most recent filing with the SEC. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.